Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase

Molecular and Cellular Endocrinology

Volumn 377, Issue 1-2, 2013, Pages 1-6

  Mologni, Luca ^a   Redaelli, Sara ^a   Morandi, Andrea ^b,d   Plaza Menacho, Ivan ^c   Gambacorti Passerini, Carlo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Gatekeeper; Ponatinib; RET; Thyroid cancer; Tyrosine kinase

Indexed keywords

CABOZANTINIB; MOTESANIB; MUTANT PROTEIN; PONATINIB; PROTEIN RET; SORAFENIB; SUNITINIB; VANDETANIB;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WILD TYPE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALL; CHRONIC MYELOID LEUKEMIA; CML; DIMETHYL SULFOXIDE; DMSO; FAMILIAL MTC; FBS; FETAL BOVINE SERUM; FMTC; GATEKEEPER; GDNF; GLIAL-DERIVED NEUROTROPHIC FACTOR; MEDULLARY THYROID CARCINOMA; MEN2; MTC; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; PAPILLARY THYROID CARCINOMA; PONATINIB; PTC; REARRANGED DURING TRANSFECTION; RET; THYROID CANCER; TKI; TYROSINE KINASE; TYROSINE KINASE INHIBITOR;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MUTANT PROTEINS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRIDAZINES;

EID: 84880361411     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.06.025     Document Type: Article

References (43)

1. Borrello M.G., Ardini E., Locati L.D., et al. RET inhibition: implications in cancer therapy. Expert Opin. Ther. Targets 2013, 17(4):403-419.
2. Carlomagno F., Salvatore D., Santoro M., et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 1995, 207(3):1022-1028.
3. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002, 62(24):7284-7290.
4. Carlomagno F., Guida T., Anaganti S., et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004, 23(36):6056-6063.
5. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 2006, 98(5):326-334.
6. Ciampi R., Nikiforov Y.E. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007, 148(3):936-941.
7. Cooley L.D., Elder F.F., Knuth A., et al. Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genet. Cytogenet. 1995, 80(2):138-149.
8. Cortes J.E., Kantarjian H., Shah N.P., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. New Engl. J. Med. 2012, 367(22):2075-2088.
9. Coxon A., Bready J., Kaufman S., et al. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J. Endocrinol. Invest. 2012, 35(2):181-190.
10. Cranston A.N., Carniti C., Oakhill K., et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res. 2006, 66(20):10179-10187.
11. De Falco V., Buonocore P., Muthu M., et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab 2013, 98(5):E811-E819.
12. Gambacorti-Passerini C., le Coutre P., Mologni L., et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 1997, 23(3):380-394.
13. Gozgit J.M., Wong M.J., Wardwell S., et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer Ther. 2011, 10(6):1028-1035.
14. Gozgit J.M., Wong M.J., Moran L., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 2012, 11(3):690-699.
15. Hart C.D., De Boer R.H. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Oncol. Targets Ther. 2013, 6:1-7.
16. Ishizaka Y., Itoh F., Tahira T., et al. Presence of aberrant transcripts of ret proto-oncogene in a human papillary thyroid carcinoma cell line. Jpn. J. Cancer Res. 1989, 80(12):1149-1152.
17. Knowles P.P., Murray-Rust J., Kjaer S., et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 2006, 23:23.
18. Lipson D., Capelletti M., Yelensky R., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 2012, 18(3):382-384.
19. Machens A., Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin. Endocrinol. (Oxf.) 2008, 69(1):81-87.
20. Machens A., Niccoli-Sire P., Hoegel J., et al. Early malignant progression of hereditary medullary thyroid cancer. New Engl. J. Med. 2003, 349(16):1517-1525.
21. Magistroni V., Mologni L., Sanselicio S., et al. ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PLoS ONE 2011, 6(11):e28162.
22. Mologni L. Development of RET kinase inhibitors for targeted cancer therapy. Curr. Med. Chem. 2011, 18(2):162-175.
23. Mologni L., Sala E., Riva B., et al. Expression, purification, and inhibition of human RET tyrosine kinase. Protein Expr. Purif. 2005, 41(1):177-185.
24. Mologni L., Sala E., Cazzaniga S., et al. Inhibition of RET tyrosine kinase by SU5416. J. Mol. Endocrinol. 2006, 37(2):199-212.
25. O'Hare T., Shakespeare W.C., Zhu X., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16(5):401-412.
26. Oxnard G.R., Arcila M.E., Chmielecki J., et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 2011, 17(17):5530-5537.
27. Pennell N.A., Daniels G.H., Haddad R.I., et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18(3):317-323.
28. Pinna G., Orgiana G., Riola A., et al. RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid 2007, 17(2):101-104.
29. Plaza-Menacho I., Burzynski G.M., de Groot J.W., et al. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet. 2006, 22(11):627-636.
30. Plaza-Menacho I., Mologni L., Sala E., et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J. Biol. Chem. 2007, 282(40):29230-29240.
31. Plaza-Menacho I., Morandi A., Mologni L., et al. Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J. Biol. Chem. 2011, 286(19):17292-17302.
32. Putzer B.M., Drosten M. The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol. Med. 2004, 10(7):351-357.
33. Quintas-Cardama A., Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin. Cancer Res. 2008, 14(14):4392-4399.
34. Redaelli S., Mologni L., Rostagno R., et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am. J. Hematol. 2012, 87(11). E125-8.
35. Sala E., Mologni L., Cazzaniga S., et al. A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: a tool to study thyroid cancer. Int. J. Biol. Macromol. 2006, 18:18.
36. Segouffin-Cariou C., Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J. Biol. Chem. 2000, 275(5):3568-3576.
37. Shifrin A.L., Xenachis C., Fay A., et al. One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome-MEN 2C?. Surgery 2009, 146(6):998-1005.
38. Smith C.C., Lasater E.A., Zhu X., et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013, 121(16):3165-3171.
39. Vitagliano D., De Falco V., Tamburrino A., et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr. Relat. Cancer 2011, 18(1):1-11.
40. Wells S.A., Robinson B.G., Gagel R.F., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 2012, 30(2):134-141.
41. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318(5853):1108-1113.
42. Zhou T., Commodore L., Huang W.S., et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des. 2011, 77(1):1-11.
43. Zuccotto F., Ardini E., Casale E., et al. Through the "gatekeeper door": exploiting the active kinase conformation. J. Med. Chem. 2010, 53(7):2681-2694.